Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Regeneron cuts White House pricing deal, offers new gene therapy for free
  • Policy / Pricing

Regeneron cuts White House pricing deal, offers new gene therapy for free

Pharmaceutical Technology

This White House deal will see Regeneron offer all its new medicines at "MFN prices", while providing Otarmeni for free to eligible patients.

Policy / PricingGene Therapy PlatformRead full story

pharminent April 24, 2026 (Last updated: April 24, 2026)

Pharmaceutical Technology

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.

Policy / PricingGene Therapy PlatformRead full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Cumberland to sell drug portfolio to Apotex for $100m
Next: Cardiometabolic trials: Using expertise to turn complexity into robust results

Related Stories

  • Policy / Pricing

EFPIA report adds to pressures on EU drug pricing policy

pharminent June 24, 2026
  • Policy / Pricing

US launches probe of German ‘underpayment’ for medicines

pharminent June 19, 2026
  • Policy / Pricing

FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’

pharminent June 19, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.